FDA reviews diabetic and HIV medications

Mar 27, 2008

The U.S. Food and Drug Administration has announced safety reviews of the FDA-approved medications Regranex Gel, Ziagen and Videx.

The FDA said study data suggests there might be an increased risk of death from cancer in diabetic patients using Regranex (becaplermin) Gel to treat leg and foot ulcers.

The FDA said it was also studying data that indicate a higher risk of heart attack in patients infected with the human immunodeficiency virus who take Ziagen (abacavir) or Videx (didanosine) as part of their drug therapy.

Until all three reviews are completed, the FDA said health care professionals should evaluate the potential risks and benefits of each drug with their patients.

Copyright 2008 by United Press International

Explore further: EU regulator: Morning-after pill OK for all women

add to favorites email to friend print save as pdf

Related Stories

Calcium makes for an environmentally friendly pickle

Jul 08, 2014

George Washington had a collection of 476 kinds of pickles. To prevent scurvy, Christopher Columbus stocked pickles on the Niña, Pinta, and Santa Maria. Julius Caesar, believing pickles to be invigorating, ...

DARPA-funded DEKA arm system earns FDA approval

May 12, 2014

DARPA launched the Revolutionizing Prosthetics program with a radical goal: gain U.S. Food and Drug Administration (FDA) approval for an advanced electromechanical prosthetic upper limb with near-natural contro ...

Engineered salmon may be a tough sell

Apr 03, 2014

The Obama administration has stalled for more than four years on deciding whether to approve a fast-growing salmon that would be the first genetically modified animal approved for human consumption.

Recommended for you

FDA approves hard-to-abuse narcotic painkiller

6 hours ago

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

6 hours ago

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

7 hours ago

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

Tough-to-abuse formulation of oxycodone approved

7 hours ago

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe pain when other ...

EU regulator: Morning-after pill OK for all women

Jul 24, 2014

(AP)—A commonly used morning-after pill is suitable for use by heavier women, the European Medicines Agency said Thursday after a review of the evidence sparked by the French manufacturer's declaration that the drugs didn't ...

Physicians warned about counterfeit medical devices

Jul 24, 2014

(HealthDay)—Physicians should be aware of the prevalence and serious consequences associated with use of counterfeit medical devices, according to a letter to the editor published online July 20 in Lasers in ...

User comments : 0